Development 143: doi:10.1242/dev.130971: Supplementary information
Table S1. Echocardiographic parameters
CI
n
HR (BMP)
LVAW;d (Depth, mm)
LVID;d (Depth, mm)
LVPW;d (Depth, mm)
LVAW;s (Depth, mm)
LVID;s (Depth, mm)
LVPW;s (Depth, mm)
LV Vol;d (ul)
LV Vol;s (ul)
%EF
% FS
LV Mass (AW) (mg)
LV Mass (AW) Corrected (mg)
Sham
Cre6
453.16± 45.96
0.69± 0.04
3.68± 0.18
0.75± 0.05
1.17± 0.1
2.11± 0.25
1.18± 0.11
58.83± 6.89
19.08± 6.21
73.57± 5.5
43.13± 4.66
89.66± 6.03
71.72± 4.82
Cre+
6
459± 18.9
0.7± 0.02
3.36± 0.12
0.63± 0.03
1.16± 0.06
1.85± 0.16
1.03± 0.07
46.58± 4.25A
11.35± 2.7
76.17± 4.75
44.88± 4.02
69.53± 6.1
55.62± 4.88A
Cre6
418.66± 24.62
0.72± 0.01
3.73± 0.02
0.67± 0.03
1.19± 0.06
2.03± 0.13
1.12± 0.07
59.36± 0.79
13.76± 2.17
76.98± 3.43
45.6± 3.27
86.85± 2.63
69.48± 2.1
P < 0.05 versus Cre+, Luc line. Cre+, iTnt-Cre;Gata4fl/fl; Cre-, NTg;Gata4fl/fl.
Development • Supplementary information
A
Cre+
8
408.12± 37.9
0.59± 0.04
4.17± 0.11A
0.6± 0.03A
0.95± 0.09
3.04± 0.2A
0.89± 0.07A
77.96± 5.03A
38.12± 5.77A
52.6± 5.23A
27.42± 3.35A
87.68± 5.81
70.14± 4.65
Development 143: doi:10.1242/dev.130971: Supplementary information
TableS2. PrimersequencesusedinqRT-PCR
Forward
AAACGGAAGCCCAAGAACCTGAAT
GGCTGACACTCTTTCCG
TGAGAACAAGCAGACCATCC
CACCGACAACTCTGTGAAGC
GGGACATCAAGGTCACCCTA
GAGGACTCGAACTCAGAACCAAGT
GTGTACAGTGCGGTGTCCAA
ACAAGATAGACCGGATCGGA
AGGCGGTGCTGTCTCTCTAT
ACTGCGTGGATTGCTACAAG
CCCTGATGGTAGCTGGAAAT
ATATCCGGTACGCCTACACC
TTAAGTTCAGGCTGGTGCTG
AGCTTTCTCCCAAGAGACCA
CAACCGGTACCTTGCTATGA
ACCTGGTGCCCAGAGACCTT
GCTCATTGTGGAGACCGATACTT
GCGGTGGGTTCTTATTGATT
ATTCCTCAACCCTGTATCGC
TATCACCCATATTAAAGCCCCATAA
CCATGACTCAAGGGAGCTTT
AGGAAGAATCTCTATTTTTGTACATTGTGT
GAGGATGTCCTCACTCGGAT
AGCCACCAGAAGAAAGTGGT
CCCAAACCAGTCACAATCAG
GAAGGGCTCATGACCACAG
PrimersequencesusedinChIP-qPCR
GATA Site on
Forward
Fgf16 Enhancer
CCCGGTCAACTATGAGAAGG
TTTTCGCTTCCTCAGACCCCTGTG
Fgf16 Control
Primersequencesusedinamplifyingfragment
Forward
Fragment
Fgf16 Promoter
CTAGCTAGCTATGCTCATTGGTGTTCCGC
Fgf16 Intron
CTAGCTAGCGTAAGTTCCAACCTTTCTAT
CTAGCTAGCGAATGAGGGTTCCAGGGAC
Fgf16 Enhancer
Reverse
GAGCTGGCCTGCGATGTCTGAGTG
CTGGTAGCAAGAATTAGAGCAT
TGAACTTCACATCTGTGGCA
CCACTTCAGCTTACCCAACA
CGCTTAGAAACTGACGCATT
CCGGTTGACGCGGAGTAG
ACCTCATCTTCTACCGGCATC
AGCCAGGAGGTCTTCCTACA
GACATTGTGGGTGACACCAT
TTTACCAAACCCAGTGATGG
CTCATCGACGTCTTTGCACT
GCCCGTGATGAGAAACTCTT
GCATGTCTCAGCTCAGGTGT
TCATGGCGTTTGTGTCCTAT
TCCGTGACCGGTAAGTATTG
GCAGGAAGAGAGAGGACTTTTGTG
TGGCAATTAGCTTCCCCTTCT
AAATTGGCAAGTCCTCATCC
ATGAGATGAGGGCTTGGTTT
AAAATTTGGCAGTCCTTCTTCCA
CTATGCCCAATCCTGAAGGT
GTTCAGGTCAACAGTGGAATCCTA
TCTCAGACCACACTGAAGCC
GCTGGGCACTAGTTGTTTGA
GGTAATGTTGCTGGCAGAGA
GATGCAGGGATGATGTTCTG
Reverse
GCCTGTCAGTTGGAAAGCTC
TTCTCTGGCCCAAAAGAGGCTG
Reverse
CCCAAGCTTGTCGGCGGCGCTCGCTTGCTC
CCCAAGCTTGTTTCTTCTGTGAGGGTGAG
CCCAAGCTTCTATATAAAGCTGCATGGG
Development • Supplementary information
Gene
Gata4
Cyclin A2
Cyclin D1
Cyclin D2
Cdk4
Gdf15
Anf
Bnp
Acta
Fhl1
Thbs1
Timp1
Col4a3
Fgf1
Fgf2
Fgf3
Fgf8
Fgf9
Fgf12
Fgf13
Fgf16
Fgf18
Vegfa
Vegfb
Vegfc
Gapdh